General Info

Founded in 2003, Marinus Pharmaceuticals is a privately held clinical stage specialty pharmaceutical company. Located in Branford, Conn., it focuses on the reformulation, development and commercialization of novel drugs to treat serious neurological, psychiatric and pain disorders. The company has completed enrollment for the Phase 2a clinical randomized, controlled trial of ganaxolone in adult uncontrolled partial-onset seizures at multiple sites around the United States. Some of its partners are Purdue Pharma, Yale University and The Epilepsy Project. Marinus Pharmaceuticals investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. The company s investors include a syndicate of premiere health care and pharmaceutical-focused venture capital investors, company founders and individuals as well as nonprofit organizations and academic organizations.